Tattoos as a risk factor for malignant lymphoma: a population-based case–control study - eClinicalMedicine thelancet.com/journals/eclin…

3-yr follow-up of TRANSFORM manalikamdar #ASCO24: - mEFS 30 mos, mPFS & OS NR - mDOR also NR - 62% of patients crossed over to liso-cel from SOC arm Look at those KM curves! 😍 #lymsm

Today at #ASCO24: In the phase 2 #TRANSCENDFL trial of CD19 #CART cell therapy lisocabtagene maraleucel in patients with 2nd line or later r/r #FollicularLymphoma, encouraging objective response rates were seen, including in high-risk second-line patients doi.org/10.1038/s41591…

We're excited to open the phase 3 randomized trial of sonrotoclax/zanubrutinib versus venetoclax/obinutuzumab in untreated CLL/SLL at CU Anschutz Medical Campus. Learn more at our CU Anschutz Division of Hematology clinical trials page below. cc manalikamdar #lymsm medschool.cuanschutz.edu/hematology/all…

Celebrating the illustrious career and retirement of Angie Falco today. 40 years of serving patients (mainly with blood cancer/MM) as an RN and then nurse practitioner. It’s been amazing working with her and will miss her greatly.

view.com.cuanschutz.edu/?qs=e6f7ba5760…

Want to hear the latest on BTK inhibitors in #MantleCellLymphoma?🤔 We just recorded an insightful session with Dr Kamdar (manalikamdar) & Dr Phillips (Tycel Phillips), coming soon to VJHemOnc.com!😁 #LYMsm #Lymphoma #HemOnc #EHA2024 European Hematology Association

CONGRESS #EHA2024 | Peter Borchmann #cioabcd presents the final analysis of phase III #HD21 trial of PET2-individualized BrECADD regimen vs intensified BEACOPP in patients with advanced-stage #HodgkinLymphoma. BrECADD had superior efficacy (PFS 94.3% vs 90.9% at 4 yr) with

Bad picture but great talk from ⁦Maria Amaya, MD PhD⁩ on STAT3 signaling in #AML at the ⁦CU Department of Medicine⁩ REACH highlights session. ⁦CU Anschutz Division of Hematology⁩ ⁦CU Cancer Center⁩

We love great news. Recently announced: Lisa Chu is a CU Department of Medicine PACE Scholar! 😀 bit.ly/CUHematologyGo…

What's new in CAR-T from #ASCO24? ☑️ Liso-Cel NCP shows Safety, Clinical Benefit in #LBCL ☑️ Dr. Lakshmi Nayak of Dana-Farber Shares Pilot Data on Axi-Cel in CNS #Lymphoma ☑️ manalikamdar Talks Liso-Cel in B-Cell Lymphomas in TRANSFORM Study and more! buff.ly/3u19Xpa

Lymphoma Classifications, How to Develop a Future Unified Taxonomy | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

New publication from the CU Lymphoma Program group with Dr. Meryl Colton, MD MSc as first author: the use of MRD monitoring to predict outcomes after tisa-cel in R/R DLBCL. #lymsm #celltherapy cc Brad Haverkos StevenBairMD manalikamdar pubmed.ncbi.nlm.nih.gov/39034202/

A warm welcome to Dr. Mat Angelos who is joining our CU Anschutz Division of Hematology leukemia program as an assistant professor. cc CU Department of Medicine CU Cancer Center #leusm

Welcome to Dr. Haley Simpson who will be joining our CU Anschutz Division of Hematology myeloma team as an instructor. cc Daniel Sherbenou, MD, PhD CU Anschutz Hematology/Oncology Fellowship CU Department of Medicine #mmsm

.5280 Magazine names this year's top medical doctors, including hematology's Tyler Buckner bit.ly/CUHematologyGo… CONGRATULATIONS TYLER!

New publication from the CU Anschutz Division of Hematology group including our lymphoma transplanter Brad Haverkos about outcomes of haplo-cord versus dual-cord transplants. #bmtsm cc Maria Amaya, MD PhD Rachel Rabinovitch Sarah Milgrom, MD Daniel Pollyea sciencedirect.com/science/articl…

Our CU Lymphoma Program chair manalikamdar is co-author of a new review in IJROBP - The Red Journal discussing the NIVAHL, AHOD1331, and pembro-GVD trials in Hodgkin lymphoma. #lymsm #radonc cc Sarah Milgrom, MD CU Anschutz Division of Hematology redjournal.org/article/S0360-…

Welcome to Jorge Monge, MD who is joining our CU Anschutz Division of Hematology myeloma division! #mmsm cc CU Cancer Center CU Department of Medicine

New publication featuring our CU Lymphoma Program faculty Drs. manalikamdar & Brad Haverkos in Blood Advances about outcomes of HGBL, NOS with CNS involvement. Congratulations to Dr. Narendranath Epperla et al. #lymsm pubmed.ncbi.nlm.nih.gov/39189932/